986 related articles for article (PubMed ID: 12680244)
1. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
3. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
5. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.
Elsässer-Beile U; Przytulski B; Gierschner D; Grussenmeyer T; Katzenwadel A; Leiber C; Deckart A; Wetterauer U
Prostate; 2000 Sep; 45(1):1-7. PubMed ID: 10960837
[TBL] [Abstract][Full Text] [Related]
7. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
9. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
11. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
12. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
Miura Y; Thoburn CJ; Bright EC; Hess AD
Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
[TBL] [Abstract][Full Text] [Related]
14. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma.
Cardi G; Heaney JA; Schned AR; Ernstoff MS
Cancer Res; 1998 May; 58(10):2078-80. PubMed ID: 9605746
[TBL] [Abstract][Full Text] [Related]
16. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
Lee S; Chong SY; Lee JW; Kim SC; Min YH; Hahn JS; Ko YW
Bone Marrow Transplant; 1997 Nov; 20(10):883-8. PubMed ID: 9404931
[TBL] [Abstract][Full Text] [Related]
17. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?
Staibano S; Mascolo M; Tranfa F; Salvatore G; Mignogna C; Bufo P; Nugnes L; Bonavolontà G; De Rosa G
Int J Immunopathol Pharmacol; 2006; 19(1):171-9. PubMed ID: 16569355
[TBL] [Abstract][Full Text] [Related]
20. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes.
Büssing A; Stein GM; Pfüller U; Schietzel M
Anticancer Res; 1999; 19(3A):1785-90. PubMed ID: 10470116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]